NEW YORK, July 20 – Informatics software provider Scimagix said this week that it had raised $25 million in a third found of private financing.

Dresdner Kleinwort Capital and EuclidSR Partners led the financing round. Tullis-Dickerson, Invesco, Future Capital, and IngleWood Ventures also participated in the financing round. Daniel Green, a director at Dresdner Kleinwort Capital, and Barbara Dalton, a partner at EuclidSR Partners, will take seats on the company’s board of directors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.